CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05147558
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:21.049386+00:00
Published At: 2026-02-27T00:00:00+00:00
Record Updated At: 2026-02-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Uterine Carcinosarcoma", "Advanced Uterine Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-27"
protocolSection.identificationModule.nctId: "NCT05147558"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.